Latest Articles
- EditorialTargeting “bad” B cells in multiple sclerosisCould laquinimod be part of the armamentarium?Thomas G. Forsthuber, Olaf StuveSeptember 21, 2016
- Views & ReviewsRestoring immune tolerance in neuromyelitis opticaPart ILarry Steinman, Amit Bar-Or, Jacinta M. Behne, et al.September 07, 2016
- Views & ReviewsRestoring immune tolerance in neuromyelitis opticaPart IIAmit Bar-Or, Larry Steinman, Jacinta M. Behne, et al.September 07, 2016
- Views & ReviewsThe topographical model of multiple sclerosisA dynamic visualization of disease courseStephen C. Krieger, Karin Cook, Scott De Nino, et al.September 07, 2016
- ArticleNeuroleptic intolerance in patients with anti-NMDAR encephalitisFlorian Lejuste, Laure Thomas, Géraldine Picard, et al.August 29, 2016
- Clinical/Scientific NotesNonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarateMoogeh Baharnoori, Jennifer Lyons, Akram Dastagir, et al.August 23, 2016
- ArticleComprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosisKeren Regev, Anu Paul, Brian Healy, et al.August 23, 2016
- ArticleDistinct T cell signatures define subsets of patients with multiple sclerosisMark C. Johnson, Emily R. Pierson, Andrew J. Spieker, et al.August 23, 2016
- Clinical/Scientific NotesLymphopenia in treatment-naive relapsing multiple sclerosisZhi Wei Lim, Elliot Elwood, Hammad Naveed, et al.August 12, 2016
Pages
Advertisement
Dr. Babak Hooshmand and Dr. David Smith